This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations
Male or female aged ≥18 years.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
Resectable non-small cell lung cancer harboring driver gene mutations.
At least one measurable disease based on Response Evaluation Criteria in Solid Tumors 1.1.
Previously treated with any anti-tumor therapy;
Subject with known autoimmune disease
Subject with known history of testing positive for human immunodeficiency virus (HIV) or known to have acquired immunodeficiency syndrome (AIDS), subject has known active hepatitis B or C.
Presence of third space effusion that cannot be controlled by drainage or other means (e.g., excessive pleural fluid and ascites).